Physician profile
Reed Michael Schmidt
NPI 1104416346
$3,579.94
in general payments reported to CMS, 2019-2025
11 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $1,692 · 2023: $1,098 · 2024: $410 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173 · Entertainment: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.39 |
| Entertainment | $566.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,296.89 | 2021-2025 | Total30, Precision 1, Dailies Total1 |
| Optos, INC. | $566.51 | 2023-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $352.92 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens |
| Abbvie INC. | $300.92 | 2022-2023 | Alphagan P, Lumigan, Vuity |
| Bausch & Lomb Americas INC. | $244.89 | 2022-2025 | |
| Glaukos Corporation | $238.17 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $229.42 | 2023-2025 | Acuvue |
| Oyster Point Pharma, INC. | $126.87 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $104.61 | 2022 | |
| Allergan, INC. | $100.00 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.